JH 04
Alternative Names: 177Lu-JH04; 68Ga-JH04; JH-04Latest Information Update: 10 Jul 2025
At a glance
- Originator Bivision Pharmaceuticals
- Class Antineoplastics; Cyclic peptides; Drug conjugates; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 10 Jul 2025 3902080 - updated - kdm , pd, pk, HE
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 01 Mar 2024 First Affiliated Hospital of Fujian Medical University initiates enrolment in a phase 0 trial for Solid tumors (Diagnosis) in China (NCT06438250)